Some major healthcare companies, including DaVita, Cigna, Encompass, CVS Health and Walmart, are sending back federal aid funding they received that was intended to help hospitals and healthcare providers during the COVID-19 pandemic.

The U.S. hit a new milestone in the COVID-19 pandemic, surpassing 100,000 deaths caused by the virus––more than anywhere else on Earth.

Testing the combined residents of the nation’s assisted living facilities and nursing homes would cost a whopping $672 million for just one round of testing.

More than 1,750 standalone Medicare Part D prescription drug plans and MA plans have applied to offer insulin at a maximum $35 copay for a month’s supply of the drug for the 2021 plan year, CMS announced.

The healthcare sector has seen an influx of funding from private equity groups over the last several years, aiding in the contraction of the industry. But has the influence of cash been beneficial for healthcare?

While emerging conventional wisdom may state biopharmaceutical companies could see a boon as a result of the COVID-19 pandemic thanks to new treatment and vaccine opportunities, the sector may not come out on top.

Testing all residents and staff at the nation’s nursing homes just once would collectively cost $440 million, according to data from the American Health Care Association and National Center of Assisted Living (AHCA/NCAL).

CVS Health has stated it will return $43 million in funding it received for COVID-19 relief.

Hospitals and healthcare providers are facing higher costs to care for complex COVID-19 patients while also suffering the loss of other procedures like elective surgeries that could help offset these higher costs.

Here’s a sampling of some of the best thinking on this body blow to the U.S. healthcare economy.

Michigan Medicine is furloughing or laying off around 1,400 fulltime employees and instituting a hiring freeze that will leave 300 current job openings unfilled. 

Plummeting healthcare spending due to COVID-19 had much to do with the U.S. gross domestic product falling 4.8% the first quarter of this year—and April’s report may bring no relief.